Navigation Links
Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
Date:12/10/2012

ed alive for more than 12 months
  • The most common treatment-emergent AEs were nausea (53 percent), diarrhea (42 percent), fatigue (39 percent), febrile neutropenia (38 percent), vomiting (37 percent), anemia (31 percent) and QT interval prolongation (27 percent). There was one occurrence of Grade 4 QT prolongation with torsade de pointes, which resolved after stopping quizartinib.  QT interval prolongations were asymptomatic, transient, and none were fatal. A total of 35 patients (27 percent) experienced an AE resulting in discontinuation of quizartinib, with the most common AE leading to discontinuation being progressive disease. 
  • Overall, responses (CRc) were achieved in over 50 percent of elderly patients with the FLT3-ITD mutation. These responses are clinically meaningful given they allowed some patients to be bridged to a stem cell transplant, and others remained alive for more than 12 months (all but one patient did not receive a HSCT). Additionally, nearly one-in-three patients without the FLT3-ITD mutation responded to quizartinib and may also benefit from its future use. Quizartinib is well tolerated, with gastrointestinal toxicities being the most common as well as reversible QT prolongation which was infrequently grade 3, with one case of Grade 4 QT prolongation, at the doses used in this trial. These data suggest that quizartinib may be an option for achieving leukemic control for elderly AML patients that no longer respond, or are refractory, following front-line chemotherapy. For a percentage of elderly AML patients who can tolerate a HSCT, quizartinib may be able to provide a bridge to potentially curative HSCT.  For those who are not HSCT candidates, prolonged quizartinib use may positively impact quality of life given its outpatient delivery.
  • Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relaps
    '/>"/>

    SOURCE Ambit Biosciences
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
    2. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
    3. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
    4. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
    5. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
    6. Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
    7. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
    8. Xstelos Holdings Announces Dividend
    9. Medbox, Inc. Announced Increased Funding for Corporate Giving Program in 2013
    10. Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs To Treat Neurological Disorders
    11. IRIDEX Corporation Announces Preliminary Results of its Tender Offer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2015)... de agosto de 2015   Royal Philips ... en el  Congreso de la ESC de 2015 ... y novedosas, entre ellas HeartModel A.I.  , EchoNavigator ... y la tecnología con los protocolos de atención ... tratamientos y permitir atención en el hogar. ...
    (Date:8/27/2015)... 27, 2015 DURECT Corporation (Nasdaq: DRRX ... at three upcoming healthcare conferences.  , ... present at the Rodman & Renshaw Investment Conference on ... conference is being held at the St. Regis Hotel ... live audio webcast of the presentation will be available ...
    (Date:8/27/2015)... MEETING, Pa. , Aug. 27, 2015  Now ... decommissioning the Da Vinci S™ surgical robot, hospitals with ... replacement plans. They also need to see where they ... procedures on the right patients? Have they adopted best ... robotic surgery program in the future? ECRI ...
    Breaking Medicine Technology:Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5DURECT to Participate in Upcoming Healthcare Conferences 2ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 2ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 3
    ... Rcadia Medical Imaging has achieved proof-of-concept with the first ... a coronary CT angiography (cCTA) study. This technology, the ... scoring, has the potential to eliminate the need for ... costs  and decrease patient radiation exposure. This work in ...
    ... The Renal Therapies Division of B. ... of the Plasmat™ Futura System for H.E.L.P. ®   ... H.E.L.P. ® therapy provides a more easy-to-use system ... patients with severe hypercholesterolemia. (Logo: http://photos.prnewswire.com/prnh/20081022/NYW008LOGO) ...
    Cached Medicine Technology:Rcadia's Fully Automatic Calcium Score Assessment from Coronary CTA Shows Potential to Eliminate Need for Separate Scan 2B. Braun Renal Therapies Division Announces Availability of Advanced Apheresis Therapy System 2
    (Date:8/28/2015)... ... 28, 2015 , ... “ Frequentz ” was featured on NewsWatch as part ... on the market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch ... allows businesses to track product movement from beginning to end. , Businesses benefit greatly ...
    (Date:8/28/2015)... ... August 28, 2015 , ... Drugs and ... James Strawbridge, gives a new approach on solutions in his new book ":Unraveling ... employer and employees getting together for meaningful group meetings. "This would educate the ...
    (Date:8/28/2015)... TN (PRWEB) , ... August 28, 2015 , ... ... recipients of the Veterans Award, honoring military veterans leading in business. Mr. ... honorees. , The inaugural Nashville Business Journal's 2015 Veterans Awards will ...
    (Date:8/28/2015)... ... August 28, 2015 , ... Dr. Gregory K. Toumayan, D.C., Q.M.E., ... resulting in shoulder pain, hip pain, neck pain, stiffness, muscle spasms, and ... the University of Illinois, and then went on to earn his title of Doctor ...
    (Date:8/28/2015)... ... , ... The Quatela Center for Plastic Surgery is excited to bring patients ... approved by the Food and Drug Administration to eliminate submental fat, also known as ... are among the premier cosmetic surgeons in Rochester to offer this innovative procedure.     ...
    Breaking Medicine News(10 mins):Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3
    ... ... that help survivors of stroke and other forms of traumatic brain injury to improve mobility, ... stroke rehabilitation, the Tailwind. (Advance for Physical Therapy and Rehab Medicine, vol. 20, issue 20, ... ...
    ... ... special woman who has everything? Why stem cells, of course! Celebrity Beauty Engineer® and ... to look and feel their best! , ... (PRWEB) December 16, 2009 -- The holidays are rapidly approaching and what kind ...
    ... new electrophoretic method for detecting MIRCERA and other erythropoietins ... has specifically enhanced sensitivity for MIRCERA, but does not ... EPOs. Details of this study, funded by a ... the latest issue of Drug Testing and Analysis ...
    ... , Consumer Watchdog Calls For Preserving State Authority, ... WASHINGTON, Dec. 15 Consumer Watchdog condemned the removal of the ... from the U.S. Senate health reform bill. But the group said ... greatly weakened bill to prevent ceding the entire health care system ...
    ... , SUNNYVALE, Calif., Dec. 15 Palo Alto ... University has deployed its PA-4000 Series next-generation firewalls for ... enhanced visibility and control over applications such as peer-to-peer ... university with eight facilities on five campuses. The university ...
    ... Dec. 15 Our Lady of Lourdes Health Care Services ... agreed to pay the United States $7.95 million to resolve ... today. The two hospitals are Our Lady of Lourdes Medical ... Burlington County (LMC) in Willingboro, N.J. , LMC is ...
    Cached Medicine News:Health News:New Tailwind Device Improves Arm Function in Stroke Survivors with Paralysis 2Health News:New Online Beauty Store Suggests Stem Cells for the Woman Who Has Everything 2Health News:Researchers discover novel method for detecting MIRCERA 2Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 2Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 3Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 4Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 5Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 2Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 3Health News:Parent Company of Two New Jersey Hospitals to Pay U.S. $7.95 Million to Settle False Claims Act Allegations 2
    Demineralized Freeze-dried Bone Allograft (DFDBA) processed from cortical bone. Demineralized cortical powder is free of all soft tissue....
    Dedicated ENT electromagnetic surgical navigation system. Value priced for comunity hospitals and surgical centers....
    ... The Summit SI Spinal Fixation ... for rigid posterior fixation of ... spine. The simplicity and versatility ... optimize the construct based on ...
    ...
    Medicine Products: